Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial - Concepedia

Concepedia

Publication | Open Access

Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial

DOI Full Paper Access

37

Citations

10

References

2019

Year

Ursula A. Matulonis, Lydia Walder, Trine Jakobi Nøttrup, Paul Bessette, Sven Mahner, Marta Gil-Martín, Elsa Kalbacher, Jonathan A. Ledermann, Robert M. Wenham, Kathrine Woie,

Journal of Clinical Oncology

Abstract

Patients who were treated with niraparib compared with RS experienced increased mean TWiST. Thus, patients who were treated with niraparib in the ENGOT-OV16/NOVA trial experienced more time without symptoms or symptomatic toxicities compared with control.

References

	Year	Citations

Page 1